12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Abilify aripiprazole regulatory update

The U.K.'s NICE issued final guidance recommending the use of Abilify aripiprazole from Otsuka and Bristol-Myers to treat moderate to severe manic episodes in adolescents ages >=13 years with bipolar I disorder. The guidance is in line with draft guidance issued in...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >